DarioHealth (NASDAQ:DRIO) Issues Quarterly Earnings Results, Beats Expectations By $9.93 EPS

DarioHealth (NASDAQ:DRIO) posted its quarterly earnings results on Thursday. The company reported $8.36 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.57) by $9.93, FiscalAI reports. DarioHealth had a negative net margin of 171.09% and a negative return on equity of 59.47%. The firm had revenue of $5.23 million for the quarter, compared to analysts’ expectations of $5.05 million.

DarioHealth Stock Performance

DRIO stock opened at $8.93 on Thursday. The stock’s 50 day simple moving average is $10.86 and its 200 day simple moving average is $11.71. DarioHealth has a 12-month low of $5.93 and a 12-month high of $17.74. The firm has a market cap of $60.37 million, a P/E ratio of -0.80 and a beta of 1.08. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41.

Institutional Trading of DarioHealth

Several institutional investors have recently added to or reduced their stakes in DRIO. XTX Topco Ltd grew its position in shares of DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of DarioHealth by 167.9% in the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after purchasing an additional 31,063 shares during the period. Finally, Kestra Advisory Services LLC bought a new stake in shares of DarioHealth during the fourth quarter valued at approximately $35,000. Institutional investors own 33.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Wall Street Zen cut shares of DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $38.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.